Global prevalence of vancomycin-resistant Enterococcus in patients with haematological malignancies: a systematic review and meta-analysis
- 1Department of Pathology, College of Medicine, Qassim University
Abstract
Background: This systematic review and meta-analysis evaluated the global prevalence of vancomycin-resistant enterococci among patients with hematological malignancies, particularly vulnerable immunocompromised populations including leukemia, lymphoma, neutropenia, and hematopoietic stem cell transplantation patients.
Methods: A systematic literature search of PubMed, Scopus, and Google Scholar was conducted for studies published up to March 2026. Eligible observational studies reporting the prevalence of VRE in patients with hematological malignancies were included. Study quality was assessed using the Joanna Briggs Institute checklist and PRISMA 2020 guidelines. Random-effects meta-analysis using logit-transformed proportions was performed in OpenMetaAnalyst and Comprehensive Meta-Analysis software. Heterogeneity was assessed using Cochran’s Q and I ² statistics. Subgroup analysis, sensitivity analysis, publication bias assessment, and meta-regression were conducted to identify potential sources of heterogeneity.
Results: A total of 120 studies involving patients with hematological malignancies were included. The pooled prevalence of VRE was 18.4% (95% CI: 15.5–21.6%), with substantial heterogeneity ( I ² = 97.56%, p < 0.001). Publication bias was detected by funnel plot asymmetry, Egger’s regression ( p = 0.0224), and Begg’s test ( p = 0.0226). Subgroup analysis demonstrated considerable geographic variation, with the highest prevalence observed in South America (25.5%) and Australia (22.8%). HSCT patients showed the highest pooled prevalence (97.1%), followed by neutropenic patients (91.2%) and acute myeloid leukemia patients (68.3%). Meta-regression identified continent as a significant contributor to heterogeneity ( Q = 11.68, p = 0.0395), whereas detection method and sample type were not significant moderators.
Conclusion: VRE represents a substantial global burden among patients with hematological malignancies, particularly in HSCT and neutropenic populations.
Systematic review registration: 10.17605/OSF.IO/2VH9D .
Related
- Risk Factors and Outcomes of Vancomycin-Resistant Enterococcus faecium Bloodstream Infection in Hematologic Malignancies and Stem Cell Transplant Recipients: A Case-Control Study
- Emergence of vancomycin-resistant and multidrug-resistant Enterococcus spp. in freshwater aquaculture systems of southeastern Nigeria: implications for one health surveillance
- Limited, outbreak-biased and unevenly reported: genomic insights into vancomycin-resistant Enterococcus faecium in Germany as reported between 2015 and 2025
- Investigating pathways of vancomycin-resistant Enterococcus (VRE) contamination and transmission in intensive care units: a prospective genomic surveillance study
- Comparative Efficacy of Vancomycin and Fidaxomicin Regimens for the Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
BibTeX
@article{aljebaly2026global,
title = {{Global prevalence of vancomycin-resistant Enterococcus in patients with haematological malignancies: a systematic review and meta-analysis}},
author = {Fatimah Suliman Mohammad Aljebaly},
journal = {Frontiers in Public Health},
year = {2026},
month = oct,
doi = {10.3389/fpubh.2026.1945305},
url = {https://www.frontiersin.org/articles/10.3389/fpubh.2026.1945305/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Global prevalence of vancomycin-resistant Enterococcus in patients with haematological malignancies: a systematic review and meta-analysis
AU - Fatimah Suliman Mohammad Aljebaly
PY - 2026
DA - 2026/10/15
JO - Frontiers in Public Health
DO - 10.3389/fpubh.2026.1945305
UR - https://www.frontiersin.org/articles/10.3389/fpubh.2026.1945305/full
AB - Background: This systematic review and meta-analysis evaluated the global prevalence of vancomycin-resistant enterococci among patients with hematological malignancies, particularly vulnerable immunocompromised populations including leukemia, lymphoma, neutropenia, and hematopoietic stem cell transplantation patients. Methods: A systematic literature search of PubMed, Scopus, and Google Scholar was conducted for studies published up to March 2026. Eligible observational studies reporting the prevalence of VRE in patients with hematological malignancies were included. Study quality was assessed using the Joanna Briggs Institute checklist and PRISMA 2020 guidelines. Random-effects meta-analysis using logit-transformed proportions was performed in OpenMetaAnalyst and Comprehensive Meta-Analysis software. Heterogeneity was assessed using Cochran’s Q and I ² statistics. Subgroup analysis, sensitivity analysis, publication bias assessment, and meta-regression were conducted to identify potential sources of heterogeneity. Results: A total of 120 studies involving patients with hematological malignancies were included. The pooled prevalence of VRE was 18.4% (95% CI: 15.5–21.6%), with substantial heterogeneity ( I ² = 97.56%, p < 0.001). Publication bias was detected by funnel plot asymmetry, Egger’s regression ( p = 0.0224), and Begg’s test ( p = 0.0226). Subgroup analysis demonstrated considerable geographic variation, with the highest prevalence observed in South America (25.5%) and Australia (22.8%). HSCT patients showed the highest pooled prevalence (97.1%), followed by neutropenic patients (91.2%) and acute myeloid leukemia patients (68.3%). Meta-regression identified continent as a significant contributor to heterogeneity ( Q = 11.68, p = 0.0395), whereas detection method and sample type were not significant moderators. Conclusion: VRE represents a substantial global burden among patients with hematological malignancies, particularly in HSCT and neutropenic populations. Systematic review registration: 10.17605/OSF.IO/2VH9D .
SN - 2296-2565
ER -